Optimizing the Dose of Glutamine Dipeptides and Antioxidants in Critically Ill Patients: A Phase I Dose-Finding Study

Abstract

Background: Supplementation with glutamine and antioxidants may be associated with an improvement in clinical outcomes, but the optimal dose of these substrates is unknown. The purpose of this study was to determine the safety of high doses of glutamine combined with antioxidants in critically ill patients. Methods: We conducted a single-center, open-label, dose-escalating clinical trial. Mechanically ventilated adult patients with clinical evidence of hypoperfusion were sequentially enrolled to 1 of 5 groups. Group 1 (n = 30): no supplementation; group 2 (n = 7): 0.35 g/kg/d of glutamine IV; group 3 (n = 7): same as group 2 plus 15 g/d of glutamine and 150 μg of selenium enterally; group 4 (n = 7): same as group 2 plus 30 g/d of glutamine and 300 μg of selenium enterally; and group 5 (n = 7): same as group 4 plus an additional 500 μg of selenium IV. After enrollment, nutrients were started as soon as possible. All patients were fed enterally according to clinical practice guidelines. Results: The primary outcomes for this study were change in sequential organ function assessment (SOFA) score and safety parameters. Secondary outcomes included whole blood glutathione (GSH), thiobarbituric acid reactive substances (TBARS), and blood cells' mitochondrial DNA/nuclear DNA ratio (RATIO). There were no adverse events attributable to the study nutrients, and the maximum and Δ SOFA did not differ across groups. In group 2, a significant decrease in GSH levels was observed (p = .03). With subsequent groups, the slopes straighten out and the p values are no longer significant, suggesting a greater preservation of GSH levels with escalating doses. In group 2, the slope of the line representing TBARS was horizontal. With subsequent groups, the slopes decrease, and by group 5, this decrease reaches statistical significance (p = .03), suggesting a greater reduction in oxidative stress with the higher doses in group 5. The difference in slopes across all groups describing the mitochondrial RATIO is statistically significant (p = .001), again suggesting that, with higher doses, there is increased mitochondrial function. Conclusions: The doses of glutamine and antioxidants tested in this study seem to be safe and may have positive effects on some mechanistic endpoints. A larger trial will be necessary to confirm their therapeutic effects.

Supplementation with glutamine and antioxidants may be associated with an improvement in clinical outcomes, but the optimal dose of these substrates is unknown. In this study, we determine the safety of high doses of glutamine and antioxidants in critically ill patients receiving enteral feedings.

Get full access to this article

View all access options for this article.

References

Heyland DK, Dhaliwal R, Drover JW, Gramlich L, Dodek P, for the Canadian Critical Care Clinical Practice Guidelines Committee. Canadian clinical practice guidelines for nutrition support in the adult critically ill patient. JPEN J Parenter Enteral Nutr.2003 ;27:355– 373.

Klein S, Kinney J, Jeejeebhoy K, et al. Nutrition support in clinical practice: review of published data and recommendations for future research directions: National Institutes of Health, American Society for Parenteral and Enteral Nutrition, and American Society for Clinical Nutrition.JPEN J Parenter Enteral Nutr .1997 ;21:133– 156.

Montejo JC, Zarazaga A, Lopez-Martinez J, et al, for the Spanish Society of Intensive Care Medicine and Coronary Units. Immunonutrition in the intensive care unit: a systematic review and consensus statement. Clin Nutr. 2003;22:221– 233.

Heyland DK. Critical care nutrition. Available at: http://www.criticalcarenutrition.com [for most recent version of meta-analyses]. Accessed January 2, 2007.

LeLorier J, Gregoire G, Benhaddad A, Lapierre J, Derderian F. Discrepancies between meta-analyses and subsequent large randomized trials.N Engl J Med . 1997;337:536– 542.

Abuja PM. When might an antioxidant become a prooxidant?Acta Anaesthesiol Scand .1998 ;42(suppl 112):229– 230.

Spallholz JE. The Negative Effects of Excessive Amounts of Naturally Occurring Selenium. Selenium-Tellurium Development Association; 1998. Available at: http://www.stda.net/publications.htm. Accessed January 2, 2007.

Miller ER, Pastor-Barriuso R, Dalal D, Riemersma RA, Appel L, Guallar E. Meta-analysis: high-dosage vitamin E supplementation may increase all cause mortality. Ann Intern Med.2005 ;142:37– 46.

Oudemans-van Straaten HM, Bosman RJ, Treskes M, van der Spoel JHI, Zandstra DF. Plasma glutamine depletion and patient outcome in acute ICU admissions. Intensive Care Med.2001 ;27:84– 90.

10.

Forceville X, Vitoux D, Gauzit R, Combes A, Lahilaire P, Chappuis P. Selenium, systemic immune response syndrome, sepsis and outcome in critically ill patients. Crit Care Med.1998 ;26:1536– 1544.

11.

Shah B, Sucher K, Hollenbeck CB. Comparison of ideal body weight equations and published height-weight tables with body mass index tables for healthy adults in the United States. Nutr Clin Pract.2006 ;21:312– 319.

12.

Marshall JC, Cook DJ, Christou NV, Bernard GR, Sprung CL, Sibbald WJ. Multiple organ dysfunction score: a reliable descriptor of a complex clinical outcome. Crit Care Med.1995 ;23:1638– 1652.

13.

Moreno R, Vincent JL, Matos R, et al. The use of maximum SOFA score to quantify organ dysfunction/failure in intensive care: results of a prospective, multicenter study. Working Group on Sepsis-related Problems of the ESICM. Intensive Care Med.1999 ;25:686– 696.

14.

Cote HC, Brumme ZL, Craib KJ, et al. Changes in mitochondrial DNA as a marker of nucleoside toxicity in HIV-infected patients. N Engl J Med. 2002;346:811– 820.

15.

Ward E, Picton S, Reid U, et al. Oral glutamine in paediatric oncology patients: a dose finding study. Eur J Clin Nutr.2003 ;57:31– 36.

16.

Tjader I, Rooyackers O, Forsberg AM, Vesali RF, Garlick PJ, Wernerman J. Effects on skeletal muscle of intravenous glutamine supplementation to ICU patients. Intensive Care Med.2004 ;30:266– 275.

17.

Littell RC, Pendergast J, Natarajan R. Modelling covariance structure in the analysis of repeated measures data. Stat Med.2000 ;19:1793– 1819.

18.

Heyland DK, Dhaliwal R, Day A, Muscedere J, Drover J, Suchner U, et al, for the Canadian Critical Care Trials Group. REducing Deaths due to OXidative Stress (The REDOXSC Study): rationale and study design for a randomzied trial of glutamine and antioxidant supplementation in critically ill patients. Proc Nutr Soc. 2006 ;65:250– 263.

19.

Lovat R, Preiser JC. Antioxidant therapy in intensive care.Curr Opin Crit Care .2003 ;9:266– 270.

20.

Brealey D, Brand M, Hargreaves I, et al. Association between mitochondrial dysfunction and severity of outcome of septic shock.Lancet . 2002;360:219– 223.

21.

Therond P, Bonnefont-Rousselot D, Davit-Spraul A, Conti M, Legrand A. Biomarkers of oxidative stress: an analytical approach. Curr Opin Clin Nutr Metab Care. 2000;3:373– 384.

22.

Novak F, Heyland DK, Avenell A, Drover J, Su X. Glutamine supplementation in serious illness: a systematic review of the evidence.Crit Care Med . 2002;30:2022– 2029.

23.

Heyland DK, Dhaliwal R, Suchner U, Berger M. Antioxidant nutrients: a systematic review of vitamins and trace elements in the critically ill patient. Intensive Care Med.2005 ;31:327– 337.

24.

Matthews DE, Marano MA, Campbell RG. Splanchnic bed utilization of glutamine and glutamic acid in humans. Am J Physiol.1993 ;264:E848– E854.

25.

Melis GC, Boelens PG, van der Sijp JRM, et al. The feeding route (enteral or parenteral) affects the plasma response of the dipeptide Ala-Gln and the amino acids glutamine, citrulline, and arginine, with the administration of Ala-Gln in preoperative patients. Br J Nutr. 2005 ;94:19– 26.

26.

Ogle CK, Ogle JD, Mao JX, et al. Effect of glutamine on phagocytosis and bacterial killing by normal and pediatric burn patient neutrophils. JPEN J Parenter Enteral Nutr.1994 ;18:128– 133.

27.

Exner R, Tamandl D, Goetzinger P, et al. Perioperative GLY-GLN infusion diminishes the surgery-induced period of immunosuppression: accelerated restoration of the lipopolysaccharide-stimulated tumor necrosis factor-alpha response. Ann Surg.2003 ;237:110– 115.

28.

Kouznetsova L, Bijlsma PB, van Leeuwen PA, Groot JA, Houdijk AP. Glutamine reduces phorbol-12,13-dibutyrate-induced macromolecular hyperpermeability in HT-29Cl.19A intestinal cells. JPEN J Parenter Enteral Nutr. 1999;23:136– 139.

29.

Kandil HM, Argenzio RA, Chen W, et al. L-glutamine and L-asparagine stimulate ODC activity and proliferation in a porcine jejunal enterocyte line.Am J Physiol . 1995;269:G591– G599.

30.

Coeffier M, Marion R, Ducrotte P, Dechelotte P. Modulating effect of glutamine on IL-1beta-induced cytokine production by human gut. Clin Nutr. 2003;22:407– 413.

31.

Manhart N, Vierlinger K, Spittler A, Bergmeister H, Sautner T, Roth E. Oral feeding with glutamine prevents lymphocyte and glutathione depletion of Peyer's patches in endotoxemic mice. Ann Surg.2001 ;234:92– 97.

32.

Heyland DK, Dhaliwal R. Immunonutrition in the critically ill: from old approaches to new paradigms. Intensive Care Med.2005 ;31:501– 503.

33.

Canadian Critical Care Trials Group. Trial of glutamine and antioxidant supplementation in critically ill patients. Available at: www.ClinicalTrials.gov ID # NCT00133978. Accessed January 16, 2006.